## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract
- **Shared manuscript claim summary** The authors report that dexamethasone, a glucocorticoid, promotes chemoresistance and stemness in lung cancer through GR-mediated nuclear translocation of beta-catenin, with the GR NTD and AF2 regions contributing to the interaction, and that GR activation correlates with worse survival and reduced chemotherapy benefit in lung cancer patients.
- **Visible evidence base** In vitro apoptosis assays, in vivo pulmonary metastatic mouse models, stemness assays, western blot, immunoprecipitation, molecular dynamics simulation, mass spectrometry, RNA-sequencing, and public transcriptomic dataset analyses (TCGA-LUAD, GEO)
- **Missing materials affecting confidence** Full methods, quantitative data, statistical details, figure legends, and dataset identifiers are not provided

## Reviewer
- **Overall assessment** The abstract presents a coherent and potentially significant hypothesis linking glucocorticoid use to chemoresistance and stemness in lung cancer via a specific molecular mechanism. The combination of in vitro, in vivo, and clinical transcriptomic analyses is commendable. However, the abstract lacks quantitative results, effect sizes, and statistical validation, making it impossible to assess the robustness of the claims. The mechanistic evidence, particularly for the GR-beta-catenin interaction, is described only qualitatively. The clinical correlation is suggestive but not causally established. The work is of interest to oncology and pharmacology audiences, but the current evidence base is insufficient to fully support the conclusions as stated.
- **Who would be interested in the results, and why** Oncologists and clinical pharmacologists concerned with glucocorticoid use in cancer patients, researchers studying chemoresistance mechanisms, and investigators focused on beta-catenin signaling and glucocorticoid receptor biology. The findings could inform clinical practice regarding dexamethasone co-administration during chemotherapy.
- **Major strengths** The study addresses a clinically relevant and under-explored question. The use of multiple complementary approaches (in vitro, in vivo, molecular, and clinical) strengthens the potential impact. The identification of specific GR domains involved in beta-catenin interaction provides mechanistic depth.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
  - R1-M4
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3
- **Assessment against Nature-style criteria** Originality is moderate to high, as the specific GR-beta-catenin mechanism in glucocorticoid-induced chemoresistance is not widely established. Scientific importance is potentially high given the routine clinical use of dexamethasone, but the abstract does not provide sufficient quantitative evidence to gauge the magnitude of the effect. Interdisciplinary readership is plausible, spanning oncology, pharmacology, and cell signaling. Technical soundness cannot be fully assessed from the abstract alone, as key methodological details and statistical analyses are missing. Readability for nonspecialists is adequate, though the mechanistic description is dense.
- **Recommendation posture** Supportive if technical concerns are resolved, particularly regarding quantitative evidence, statistical rigor, and mechanistic validation.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence sufficiency
- **Claim pointer** The abstract claims that dexamethasone pre-treatment significantly suppressed apoptosis and reduced paclitaxel anti-tumor efficiency in vivo.
- **Evidence pointer** Methods section, in vitro and in vivo assays, location not provided
- **Concern** The abstract states that dexamethasone suppressed apoptosis and reduced paclitaxel efficacy, but no quantitative data, effect sizes, or statistical significance values are provided. The term "significantly" is used without supporting metrics.
- **Why it matters** Without quantitative results, the reader cannot evaluate the magnitude or reliability of the observed effects, which are central to the paper's conclusions.
- **Resolution test** Provide specific numerical data (e.g., percent apoptosis, tumor volume reduction) with statistical tests and p-values or confidence intervals for all key experiments.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Mechanistic validation
- **Claim pointer** The abstract claims that dexamethasone-induced chemoresistance and stemness depend on GR-mediated nuclear translocation of beta-catenin, with NTD and AF2 regions of GR contributing to the interaction.
- **Evidence pointer** Methods section, western blot, immunoprecipitation, molecular dynamics simulation, location not provided
- **Concern** The mechanistic evidence is described only qualitatively. It is unclear whether loss-of-function or rescue experiments were performed to establish causality, and whether the molecular dynamics simulation results are experimentally validated.
- **Why it matters** The central mechanistic claim requires demonstration that disrupting GR-beta-catenin interaction abolishes the observed phenotypes, not just correlative binding data.
- **Resolution test** Include functional experiments (e.g., GR mutants lacking NTD or AF2, beta-catenin knockdown) showing that the phenotypes are dependent on the proposed interaction, and provide quantitative binding data from immunoprecipitation and simulation.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Clinical correlation validity
- **Claim pointer** The abstract claims that GR activation is associated with worse survival and less benefit from chemotherapy in lung cancer patients based on TCGA-LUAD and GEO datasets.
- **Evidence pointer** Methods section, public dataset analyses, location not provided
- **Concern** The abstract does not specify how GR activation was defined or measured in the transcriptomic data, nor does it provide hazard ratios, confidence intervals, or adjustment for confounders. The association is stated without statistical detail.
- **Why it matters** Clinical claims require robust statistical reporting to assess the strength and independence of the association, especially given the potential for confounding in retrospective analyses.
- **Resolution test** Provide the GR activation signature or metric used, multivariate analysis results, and effect sizes with confidence intervals for survival and chemotherapy response outcomes.

- **Concern ID** R1-M4
- **Severity** Major
- **Blocking** No
- **Axis** Reproducibility
- **Claim pointer** The abstract implies that the findings are generalizable to lung cancer, but the specific models and cell lines are not described.
- **Evidence pointer** Methods section, in vitro and in vivo assays, location not provided
- **Concern** The abstract does not specify which lung cancer cell lines or animal models were used, nor the number of biological replicates. This limits the ability to assess the generalizability and reproducibility of the findings.
- **Why it matters** Reproducibility is a core scientific standard, and the lack of model details prevents other researchers from replicating or building on the work.
- **Resolution test** List the cell lines, animal strains, sample sizes, and replicate numbers in the methods or results.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Abstract wording
- **Evidence pointer** Aims section, location not provided
- **Issue** The phrase "growing evidences" is grammatically incorrect and should be "growing evidence."
- **Required correction** Revise to "growing evidence" for grammatical accuracy.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Completeness
- **Affected element** Clinical dataset details
- **Evidence pointer** Results section, location not provided
- **Issue** The abstract mentions TCGA-LUAD and GEO datasets but does not specify which GEO datasets were used or the number of patients analyzed.
- **Required correction** Provide dataset identifiers and sample sizes for the clinical analyses.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Terminology
- **Affected element** Mechanistic description
- **Evidence pointer** Results section, location not provided
- **Issue** The term "nuclear-translocation of GR/beta-catenin complex" is ambiguous, as it is unclear whether the complex forms before or after translocation.
- **Required correction** Clarify the sequence of events, e.g., "GR-mediated nuclear translocation of beta-catenin" or "translocation of the GR-beta-catenin complex."

## Risk / unsupported claims
- The claim that dexamethasone promotes chemoresistance and stemness is not quantitatively supported in the abstract.
- The mechanistic dependence on GR-beta-catenin interaction is not causally established from the described evidence.
- The clinical association between GR activation and worse outcomes is not statistically substantiated.
- The generalizability of the findings to all lung cancer types is unsubstantiated given unspecified models.